Nancy Reau to Treatment Outcome
This is a "connection" page, showing publications Nancy Reau has written about Treatment Outcome.
Connection Strength
0.853
-
Changing epidemiology, implications, and recommendations for hepatitis C in women of childbearing age and during pregnancy. J Hepatol. 2021 03; 74(3):734-741.
Score: 0.098
-
Review article: a treatment algorithm for patients with chronic liver disease and severe thrombocytopenia undergoing elective medical procedures in the United States. Aliment Pharmacol Ther. 2020 10; 52(8):1311-1322.
Score: 0.096
-
Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection. Hepatology. 2018 10; 68(4):1298-1307.
Score: 0.083
-
Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir With or Without Ribavirin in HCV-Infected Patients Taking Concomitant Acid-Reducing Agents. Am J Gastroenterol. 2016 06; 111(6):845-51.
Score: 0.071
-
HCV Council--critical appraisal of data: recommendations for clinical practice in a rapidly evolving therapeutic landscape. Liver Int. 2016 Apr; 36(4):488-502.
Score: 0.069
-
Sticker shock and the price of new therapies for hepatitis C: is it worth it? Hepatology. 2014 Apr; 59(4):1246-9.
Score: 0.061
-
Characterization of nonrapid virologic response patients infected with HCV genotype 1 who may relapse after standard therapy with peginterferon plus ribavirin. J Viral Hepat. 2012 Feb; 19(2):94-102.
Score: 0.049
-
Evaluation of early null response to pegylated interferon and ribavirin as a predictor of therapeutic nonresponse in patients undergoing treatment for chronic hepatitis C. Am J Gastroenterol. 2011 Mar; 106(3):452-8.
Score: 0.049
-
Long-term outcomes after treatment with interferon and ribavirin in HCV patients. J Clin Gastroenterol. 2009 Aug; 43(7):661-71.
Score: 0.045
-
Early predictors of anemia in patients with hepatitis C genotype 1 treated with peginterferon alfa-2a (40KD) plus ribavirin. Am J Gastroenterol. 2008 Aug; 103(8):1981-8.
Score: 0.042
-
Patient-reported outcomes 12?months after hepatitis C treatment with direct-acting antivirals: Results from the PROP UP study. Liver Int. 2021 04; 41(4):692-704.
Score: 0.025
-
Hepatitis C remains leading indication for listings and receipt of liver transplantation for hepatocellular carcinoma. Dig Liver Dis. 2020 01; 52(1):98-101.
Score: 0.023
-
Resistance analysis in patients with genotype 1-6 HCV infection treated with sofosbuvir/velpatasvir in the phase III studies. J Hepatol. 2018 05; 68(5):895-903.
Score: 0.020
-
Hepatitis C Virus Infection Care Pathway-A Report From the American Gastroenterological Association Institute HCV Care Pathway Work Group. Gastroenterology. 2017 05; 152(6):1588-1598.
Score: 0.019
-
Patient engagement and study design of PROP UP: A multi-site patient-centered prospective observational study of patients undergoing hepatitis C treatment. Contemp Clin Trials. 2017 06; 57:58-68.
Score: 0.019
-
Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With?Genotype 1 Hepatitis C Virus Infection in an Open-Label, Phase 2 Trial. Gastroenterology. 2016 11; 151(5):893-901.e1.
Score: 0.018
-
Ribavirin-Free Regimen With Sofosbuvir and Velpatasvir Is Associated With High Efficacy and Improvement of Patient-Reported Outcomes in Patients With Genotypes 2 and 3 Chronic Hepatitis C: Results From Astral-2 and -3 Clinical Trials. Clin Infect Dis. 2016 10 15; 63(8):1042-1048.
Score: 0.018
-
The benefit of paracentesis on hospitalized adults with cirrhosis and ascites. J Gastroenterol Hepatol. 2016 May; 31(5):1025-30.
Score: 0.018
-
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. N Engl J Med. 2015 Dec 31; 373(27):2608-17.
Score: 0.017
-
Co-management between hospitalist and hepatologist improves the quality of care of inpatients with chronic liver disease. J Clin Gastroenterol. 2014 Apr; 48(4):e30-6.
Score: 0.015